Patents Assigned to Gansu Evergreen Pharmaceuticals, Co., Ltd.
  • Use of Ovatodiolide against SARS-CoV-2
    Publication number: 20230143813
    Abstract: A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.
    Type: Application
    Filed: April 17, 2020
    Publication date: May 11, 2023
    Applicants: Peking University Shenzhen Graduate School, CNS Biotek Corp., Gansu Evergreen Pharmaceuticals, Co., Ltd.
    Inventors: Zhen Yang, Yew-Min Tzeng, Linqi Zhang, Junmin Quan, Qing Chang, Qi Zhang, Chien-Ming Lee